In this study, although both LAT1 and 4F2hc were expressed in both tumor cells and vascular endothelia of glioma tissues, and there was a significant association between LAT1 expression and 4F2hc expression, the expression level and location of LAT1 and 4F2hc was not completely parallel, i.e. in general, the 4F2hc immunostaining was more intensive than LAT1 immunostaining in glioma tissues, and moreover, LAT1 immunoreactivity was markedly stronger than 4F2hc immunoreactivity in vascular endothelia. Here, SLC3A2 is linked to central nervous system cancer.